Merck has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire SpringWorks ...

The FDA has granted rare paediatric disease and orphan drug designations for IN013, Innorna's mRNA therapeutic for Wilson's ...

Amgen has announced a significant expansion of the Ohio manufacturing facility in the US, with an investment of $900m.

China’s NMPA has approved InnoCare Pharma’s orelabrutinib for use as a first-line treatment for CLL and small lymphocytic ...

Caribou is scaling back its operations, halting multiple programmes, and cutting staff to focus on two cancer programmes.

Following in the footsteps of several pharma companies, life sciences giant Thermo Fisher is doubling down on investments at ...

The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

The EC has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD).

Mochi Health, one of those implicated, is one of the largest telehealth providers of compounded GLP-1RAs. Eli Lilly maintains ...

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Granite Bio has secured $100m in funding for its new antibody treatments that target several autoimmune diseases.